These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 34787028)

  • 1. Polycystic ovarian syndrome: signs and feedback effects of hyperandrogenism and insulin resistance.
    Hernández-Jiménez JL; Barrera D; Espinoza-Simón E; González J; Ortíz-Hernández R; Escobar L; Echeverría O; Torres-Ramírez N
    Gynecol Endocrinol; 2022 Jan; 38(1):2-9. PubMed ID: 34787028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
    Nestler JE
    Semin Reprod Endocrinol; 1997 May; 15(2):111-22. PubMed ID: 9165656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperandrogenism and Insulin Resistance, Not Changes in Body Weight, Mediate the Development of Endothelial Dysfunction in a Female Rat Model of Polycystic Ovary Syndrome (PCOS).
    Hurliman A; Keller Brown J; Maille N; Mandala M; Casson P; Osol G
    Endocrinology; 2015 Nov; 156(11):4071-80. PubMed ID: 26322372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutrient-Induced Inflammation in Polycystic Ovary Syndrome: Role in the Development of Metabolic Aberration and Ovarian Dysfunction.
    González F
    Semin Reprod Med; 2015 Jul; 33(4):276-86. PubMed ID: 26132932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin sensitizers in polycystic ovary syndrome.
    Pasquali R; Gambineri A
    Front Horm Res; 2013; 40():83-102. PubMed ID: 24002407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.
    Rosenfield RL; Ehrmann DA
    Endocr Rev; 2016 Oct; 37(5):467-520. PubMed ID: 27459230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperinsulinism and its interaction with hyperandrogenism in polycystic ovary syndrome.
    Sozen I; Arici A
    Obstet Gynecol Surv; 2000 May; 55(5):321-8. PubMed ID: 10804539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
    Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
    Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycystic ovary syndrome and insulin-resistant hyperinsulinemia.
    Rosenfield RL
    J Am Acad Dermatol; 2001 Sep; 45(3 Suppl):S95-104. PubMed ID: 11511859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity.
    Zeng X; Xie YJ; Liu YT; Long SL; Mo ZC
    Clin Chim Acta; 2020 Mar; 502():214-221. PubMed ID: 31733195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.
    Unlühizarci K; Keleştimur F; Bayram F; Sahin Y; Tutuş A
    Clin Endocrinol (Oxf); 1999 Aug; 51(2):231-6. PubMed ID: 10468995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic and other effects of pioglitazone as an add-on therapy to metformin in the treatment of polycystic ovary syndrome (PCOS).
    Valsamakis G; Lois K; Kumar S; Mastorakos G
    Hormones (Athens); 2013; 12(3):363-78. PubMed ID: 24121378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperinsulinemia and ovarian hyperandrogenism. Cause and effect.
    Barbieri RL; Hornstein MD
    Endocrinol Metab Clin North Am; 1988 Dec; 17(4):685-703. PubMed ID: 3058472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgens in polycystic ovary syndrome: the role of exercise and diet.
    Giallauria F; Palomba S; Vigorito C; Tafuri MG; Colao A; Lombardi G; Orio F
    Semin Reprod Med; 2009 Jul; 27(4):306-15. PubMed ID: 19530064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The management of insulin resistance in polycystic ovary syndrome.
    Teede HJ; Hutchison SK; Zoungas S
    Trends Endocrinol Metab; 2007 Sep; 18(7):273-9. PubMed ID: 17698366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel insights into the synergistic effects of selenium nanoparticles and metformin treatment of letrozole - induced polycystic ovarian syndrome: targeting PI3K/Akt signalling pathway, redox status and mitochondrial dysfunction in ovarian tissue.
    Rabah HM; Mohamed DA; Mariah RA; Abd El-Khalik SR; Khattab HA; AbuoHashish NA; Abdelsattar AM; Raslan MA; Farghal EE; Eltokhy AK
    Redox Rep; 2023 Dec; 28(1):2160569. PubMed ID: 36661246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects.
    Nardo LG; Rai R
    Gynecol Endocrinol; 2001 Oct; 15(5):373-80. PubMed ID: 11727360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycystic ovary syndrome.
    Goudas VT; Dumesic DA
    Endocrinol Metab Clin North Am; 1997 Dec; 26(4):893-912. PubMed ID: 9429864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycystic ovary syndrome (PCOS) and the accompanying disorders of glucose homeostasis among girls at the time of puberty.
    Otto-Buczkowska E; Grzyb K; Jainta N
    Pediatr Endocrinol Diabetes Metab; 2018; 24(1):40-44. PubMed ID: 30083660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.